# US 2016/0251401 A1 · Method for increasing etec cs6 antigen presentation on cell surface and products obtainable thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251401 A1
- Document ID: US20160251401A1
- Status: Published application
- Kind: A1
- Application number: 15/009,645
- Filed: 2016-01-28
- Published: 2016-09-01
- Earliest claimed: 2011-09-12
- Assignees: Scandinavian Biopharma Holding AB
- Applicants: Scandinavian Biopharma Holding AB
- Inventors: Nils Carlin; Ann-Mari Svennerholm; Joshua Tobias
- Web page: https://patentgrep.com/patent/US20160251401A1

## CPC

- C07K 14/245: Escherichia (G)
- A61K 39/001102: {Receptors, cell surface antigens or cell surface determinants}
- A61K 39/0258: {Escherichia}
- A61P 31/04: Antibacterial agents
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/0011: {Cancer antigens}
- A61K 2039/521: {inactivated (killed)}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/575: {humoral response}
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- G01N 33/56916: {Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A method for increasing the presentation of ETEC CS6 antigen on cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against CS6-expressing ETC. Cells and vaccines obtainable by the above methods.

## Claims

### Claim 1

(canceled)

### Claim 2

A phenol-treated cell having an amount of enterotoxigenic Escherichia coli “ETEC” Coli surface antigen 6 “CS6” antigen on a cell surface greater than an untreated cell.

### Claim 3 (depends on 2)

The cell according to claim 2, wherein the amount of said antigen on the cell surface is at least 100% greater than an untreated cell.

### Claim 4 (depends on 3)

The cell according to claim 3, wherein the amount of said antigen on the cell surface is at least 200% greater than an untreated cell.

### Claim 5 (depends on 4)

The cell according to claim 4, wherein the amount of said antigen on the cell surface is at least 300% greater than an untreated cell.

### Claim 6 (depends on 2)

The cell according to claim 2, wherein the cell was treated with 0.6 to 2.0 percent phenol by weight for a duration of 1 to 72 h.

### Claim 7 (depends on 6)

The cell according to claim 6, wherein the cell was treated for a duration of 1.5 to 42 h.

### Claim 8 (depends on 2)

The cell according to claim 2, wherein the cell was treated with 0.6 to 2.0 percent phenol by weight at a temperature of 18 to 42° C.

### Claim 9 (depends on 6)

The cell according to claim 6, wherein the cell was treated at a temperature of 18 to 42° C.

### Claim 10 (depends on 9)

The cell according to claim 9, wherein cell was treated at a temperature of 18 to 38° C.

### Claim 11 (depends on 10)

The cell according to claim 10, wherein the cell was treated at a temperature of 18 to 22° C.

### Claim 12 (depends on 10)

The cell according to claim 10, wherein the cell was treated at a temperature of is 36 to 38° C.

### Claim 13 (depends on 8)

The cell according to claim 8, wherein the cell was treated with a phenol concentration of 0.8-2.0 percent by weight.

### Claim 14 (depends on 13)

The cell according to claim 13, wherein the cell was treated with a phenol concentration of 1.0-2.0 percent by weight.

### Claim 15 (depends on 8)

The cell according to claim 8, wherein the cell was treated with a phenol concentration of 0.6-2.0 percent by weight, for a time of 6-72 h and at temperature of 18-22° C.

### Claim 16 (depends on 15)

The cell according to claim 15, wherein the cell was treated at a phenol concentration of 0.75-0.85 percent by weight, for a time of 40±2 h and at a temperature of 20±1° C.

### Claim 17 (depends on 2)

The cell according to claim 2, wherein the cell is an Escherichia coli cell.

### Claim 18 (depends on 2)

The cell according to claim 2, wherein the antigen is recombinantly overexpressed by the cells.

### Claim 19 (depends on 2)

The cell according to claim 2, wherein the cell is a killed whole cell.

### Claim 20 (depends on 19)

The cell according to claim 19, wherein the cell is an Escherichia coli cell.

### Claim 21 (depends on 2)

An immunogenic composition, comprising the cell according to claim 2.

### Claim 22 (depends on 21)

The immunogenic composition according to claim 21, wherein the cell is an Escherichia coli cell.

### Claim 23 (depends on 22)

The immunogenic composition according to claim 22, wherein the cell is a killed whole cell.

### Claim 24 (depends on 16)

An immunogenic composition, comprising the cell according to claim 16.

### Claim 25 (depends on 24)

The immunogenic composition according to claim 24, wherein the cell is an Escherichia coli cell.

### Claim 26 (depends on 25)

The immunogenic composition according to claim 25, wherein the cell is a killed whole cell.
